Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas

Abstract

This article reports densities and viscosities up to 60 MPa and from 303.15 to 353.15 K on two binary mixtures of CO2 and lubricant pentaerythritol tetra‐2‐ethylhexanoate with 7.8% and 14.4% mass fraction of lubricant. Because CO2 and the lubricant are not in the same phase at atmospheric pressure and room temperature, a specially‐designed vibrating‐wire apparatus has been used. The experimental data, together with our previous data for six mixtures of CO2 and three polyolesters, have been used to test the predictive and correlation ability of several models: simple mixing laws, the self‐referencing method, and the hard‐sphere and free volume models. In general, it is not possible to predict the viscosity with deviations smaller than 10%. The hard‐sphere model and the self‐referencing model are the more adequate to represent the viscosity of these mixtures. Most of the models studied underestimate the viscosities over the investigated (T,p) range. © 2008 American Institute of Chemical Engineers AIChE J, 2008

Elevated Serum Ghrelin Exerts an Orexigenic Effect that May Maintain Body Mass Index in Patients with Metastatic Neuroendocrine Tumors

“…2, no positive correlation is seen between ghrelin and chromogranin A, a biochemical marker for NETs, in patients with hepatic metastases. In previous studies, CgA has been shown to have low sensitivity and specificity for detecting tumor increases and stabilization (Abou-Saif et al 2003). It therefore is not surprising to see poor correlation here.…”

68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors

“…It might well be that the 3-mo follow-up after PRRT was too brief an interval for detecting true responses by tumor markers, especially given that there may have been a paradoxic elevation (i.e., due to treatment-related secretion) in the early posttreatment reassessment. Basically, the plasma chromogranin A level had low specificity for predicting changes in tumor size among human gastrinoma patients and varied considerably from day to day (32). In several previous clinical studies, chromogranin A levels failed to correlate with the NET mass (33)(34)(35)(36)(37)(38).…”

Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art

“…Moreover, several recent therapeutic trials on NETs demonstrated its prognostic value , Yao et al 2011b. Several authors reported correlations between CgA variations during treatment and RECIST-assessed tumor evolution (Bajetta et al 1999, Seregni et al 2001, Abou-Saif et al 2003, Kouvaraki et al 2004, Nehar et al 2004, Jensen et al 2007, Yao et al 2011b. Early CgA response (R30% decrease at week 4) was correlated with improved median PFS, median OS, and tumor responses, compared with patients without early CgA responses (Table 3; Yao et al 2010a, 2011b.…”